Showing 3071-3080 of 5256 results for "".
- Efficacy Data for LaViv Now Publishedhttps://practicaldermatology.com/news/20120418-efficacy_data_for_laviv_now_published/2459822/Data demonstrating that LaViv (azficel-T, Fibrocell Science, Inc.) is effective for the aesthetic improvement of moderate to severe smile lines are now published online in Dermatologic Surgery. The combined results of two identically-designed, Phase III, multi-
- La Roche-Posay Launches Mobile “Dermatologist By Your Side” Educationhttps://practicaldermatology.com/news/20120320-la_roche-posay_launches_mobile_dermatologist_by_your_side_education/2459835/When patients want advice on skin care products in the pharmacy or anywhere, they can dial **DERM from a mobile phone. An automated text response leads them to a dedicated YouTube.com site, featuring educational videos from dermatologists Kavita Mariwala, MD and Shirley Chi, MD. The program from
- EHR iPad App Now Features Speech Recognitionhttps://practicaldermatology.com/news/20120320-ehr_ipad_app_now_features_speech_recognition/2459838/The EZ DERM EHR iPad app is now powered by the cloud-based Nuance Healthcare 360 | Development Platform. The speech recognition platform provides CPU intensive speech and
- Galderma Completes Phase 3 Rosacea Erythema Studyhttps://practicaldermatology.com/news/20120320-galderma_completes_of_phase_3_rosacea_erythema_study/2459839/Galderma Laboratories announced the completion of two independent Phase 3 clinical trials that evaluated the safety and efficacy of CD07805/47, a proprietary topical gel under investigation in patients with moderate to severe facial erythema of
- Health Care Fraud Prevention and Enforcement Efforts Net Nearly $4.1Bhttps://practicaldermatology.com/news/20120302-health_care_fraud_prevention_and_enforcement_efforts_net_nearly_41b/2459856/Attorney General Eric Holder and Department of Health and Human Services (HHS) Secretary Kathleen Sebelius today released a new report showing that the government's health care fraud prevention and enforcement efforts recovered nearly $4.1 billion in taxpayer dollars in Fiscal Year (FY) 2011. This
- Sciton Expanding in Canadahttps://practicaldermatology.com/news/20120229-sciton_expanding_in_canada/2459860/Sciton, Inc., is establishing a direct presence in Canada. Noting a very strong and loyal customer base within Canada, the company says it views the Canadian market as an integral part of its corporate growth strategy. Sciton will expand its marketing, sales, clinical education and service offerings
- The Medical Entrepreneur Symposium Announces Sponsorshttps://practicaldermatology.com/news/20120229-the_medical_entrepreneur_symposium_announces_sponsors/2459863/The Medical Entrepreneur Symposium has finalized agreements with several initial sponsors for its upcoming educational seminar. Citrix GotoMeeting, AdvancedMD, Bernstein Wealth Management, Allergan Cosmetic, Obagi, Merz Aesthetics, and BTL Exilis have all agreed to sponsor the two-and-a-half-day sym
- Early Data Presented for Celotres™ for Keloid Scarshttps://practicaldermatology.com/news/20120224-early_data_presented_for_celotres_for_keloid_scars/2459866/Results from Halscion, Inc.'s KLEAR Study, which evaluated the initial safety and efficacy of Celotres™ in the treatment of keloid scars adjunctive to surgical excision, show a significant reduction (p=0.0110) in keloid recurrence, as compared to scientific literature, following a single treatment o
- Ulthera to Expand Operationshttps://practicaldermatology.com/news/20120210-ulthera_to_expand_operations/2459868/Ulthera, Inc. (www.ultherapy.com) is expanding its operations to include the manufacturing of various components of its technology, part of a growth plan anticipated to create more than 100 new, high-wage jobs and result in $1.68 milli
- Ivarmacitinib Demonstrates Efficacy in Phase 3 Trial for Atopic Dermatitishttps://practicaldermatology.com/news/ivarmacitinib-demonstrates-efficacy-in-phase-3-trial-for-atopic-dermatitis/2474409/A new Phase 3 randomized clinical trial shows that ivarmacitinib, an oral JAK1 inhibitor, significantly improves clinical signs of moderate to severe atopic dermatitis (AD) in both adolescents and adults with a favorable safety profile.